Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.

Ana DomingosThe Domingos Group specialises in the study of sympathetic neurons and what goes wrong with these neurons in the context of obesity. In 2015, Professor Ana Domingos and her team discovered that these neurons are essential for the biology of the adipose tissue by uncovering the sympathetic neuro-adipose junction, a functional synapse-like connection between white adipocytes and the sympathetic nervous system, which is required for the reduction of fat mass.

The Domingos lab has now discovered the existence of another population of cells that are hypothesised to be controlling the biology of sympathetic neurons. With a new Global Obesity ASPIRE competitive grant from Pfizer, the research team will study the role of perineurial cells and how they cross talk with sympathetic neurons and adipocytes to control fat mass. If researchers can better understand the biology behind this cross talk, the hope is that potential drug targets can be identified in future research.

Pfizer Global Medical Grants (GMG) aims to support independent initiatives from the global healthcare community to improve patient outcomes in areas of unmet medical need. The selection process for the latest public Request for Proposal (RFO) was very competitive, with just 2.5% of applicants receiving a research grant. The GMG panel recognised that uncovering the role of sympathetic-associated perineurial barrier cells in controlling body weight is an important question and is supported by a large amount of strong preliminary data already generated by the Domingos Group. Consequently, the GMG awarded $250K to fund Professor Domingos and her lab for the next three years, one of just give proposals to receive funding.

Professor Ana Domingos said: "Pfizer is funding curiosity-driven research on mechanisms that are related to the homeostasis of body weight. The earlier the research stage that is being funded, the more likely it is that you are going to make meaningful discoveries that can change the approach to obesity related diseases. I believe this grant will lead us to understanding the sympathetic nervous system better, and also to understanding why sympathetic neurons are dying. Why are they dying in the process of obesity? And can we stop that? To answer this question, we need to understand what are the key players and variables in this equation."

More information on Pfizer's Competitive Grants Program.



Similar stories

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Professor Dame Frances Ashcroft to receive Vanderbilt Prize in Biomedical Science

The Vanderbilt Prize in Biomedical Science recognises women scientists with a stellar record of research accomplishments who also have made significant contributions to mentoring other women in science.

Annie Park to advance our understanding of how the brain encodes reward with new Wellcome Trust Award

Congratulations are in order for Postdoctoral Fellow Dr Annie Park who has been awarded a prestigious Wellcome Early-Career Award.

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Unlocking the Secrets of cAMP Signalling in the Heart: A Pathway to Targeted Therapeutics

A new Zaccolo group study has revealed key new insights into the role of cAMP signalling in both healthy and disease settings within the heart. They have identified new cAMP nanodomains in cardiac muscle cells that have far reaching implications for the treatment of heart disease.